Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases - Wikidata - wikimedia - TriplyDB

Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases

Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases

http://www.wikidata.org/entity/Q33447971

about

Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer.Prognostic factors for patients with bone-only metastasis in breast cancer Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases Anti-cancer actions of denosumab.Alendronate affects osteoblast functions by crosstalk through EphrinB1-EphB.Nephrotic syndrome and renal failure in a patient with metastatic breast cancer.

P2860

Q36075231-6D0E8900-72DB-4608-82C5-CCF65EF7C321 Q37094622-30CD1B99-E89B-4129-8121-5FD19D8B24D9 Q37335234-C007A95B-2809-408A-AEA8-1699B6A46C58 Q37483543-51B70A36-59F9-4C56-A7CF-431306C5DBC7 Q37923343-11AB7ECA-4D59-4478-963A-9D18B2ACF024 Q40947747-E49468EE-484D-448B-BBAF-FAA70E9F1F52 Q51490614-95C0C3FD-817C-4BAC-9E89-F4186131AE8A

P2860

Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases

http://www.wikidata.org/entity/Q33447971

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Potential antitumor effects of ...... patients with bone metastases

@ast

Potential antitumor effects of ...... patients with bone metastases

@en

type

label

Potential antitumor effects of ...... patients with bone metastases

@ast

Potential antitumor effects of ...... patients with bone metastases

@en

prefLabel

Potential antitumor effects of ...... patients with bone metastases

@ast

Potential antitumor effects of ...... patients with bone metastases

@en

P1433

Q33447971-32866525-FB87-4216-9C4D-67BE181AD809

P1476

Q33447971-1DEF9728-51DD-4C4B-BAD5-9CEC61D1542D

P2093

Q33447971-30E21AD3-AB92-4FA4-8B4D-F52F4BCD4EFB

Q33447971-62CF05DD-9E03-433F-9A78-F19407C0CFDD

Q33447971-6376D06C-20F1-43BC-898D-1A4343F80A5C

Q33447971-660EDD40-A5FF-46B7-9B7D-5933C9F02D0B

Q33447971-75667E66-43FF-4021-9F2A-71D84C6D6310

P2860

Q33447971-0FB84CFB-ECBA-4A03-84FF-0F28589ABC84

Q33447971-1C829788-26BF-432F-B59F-C4A98AE9A5FC

Q33447971-266660EC-4152-4F6E-8C3A-9BF4DEDA5A84

Q33447971-266C1E30-8E24-42B3-A4C4-EA9F3F5D0EB3

Q33447971-2997DD1F-82D6-4283-9E84-5A8256C3E35F

Q33447971-3C38200D-DEA0-44BF-B121-E5972372BADB

Q33447971-6378BECC-3917-4454-960A-62CD69E7B8DB

Q33447971-65861C31-E90C-4BC6-96D5-31560685AE47

Q33447971-775CCD66-3456-4297-83DD-9E9D168DCC05

Q33447971-7A01CBDC-D0C8-4A6B-955D-7961B42DD058

P2888

Q33447971-BB994B2F-6E7F-4EFE-9012-2533D24AF094

P304

Q33447971-04177185-4E63-4DAA-B3D6-1B6AB5219CF4

P31

Q33447971-8E0C477F-ABA0-4F1E-934F-B93FE543E27D

P356

Q33447971-FB8F841C-BDD3-45E2-A54E-EE1DA0953D0C

P407

Q33447971-C234BC5C-010F-4D4D-9627-09D66D6FB995

P478

Q33447971-8B009610-B81F-4FEC-8560-AE1D769203E2

P577

Q33447971-BBA4F074-466F-4C9C-9E36-D18B393D418D

P5875

Q33447971-AD54C0E7-203A-4FD4-845A-6A08C2129E80

P6179

Q33447971-0E908566-DC84-4E63-9ADF-C70376895010

P698

Q33447971-57AC13E0-8ABD-46BE-9D90-F8D67B4ECCE4

P932

Q33447971-09CBC07B-6BBF-473D-B22A-ECD55B205ACB

P356

1471-2407-9-154

P1433

P1476

Potential antitumor effects of ...... patients with bone metastases

@en

P2093

Byung Ho Nam

http://www.w3.org/2001/XMLSchema#string

In Hae Park

http://www.w3.org/2001/XMLSchema#string

Jungsil Ro

http://www.w3.org/2001/XMLSchema#string

Keun Seok Lee

http://www.w3.org/2001/XMLSchema#string

Youngmi Kwon

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

Metastasis to bone: causes, consequences and therapeutic opportunities

Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Prevention of bone metastases from breast cancer by adjuvant bisphosphonate therapy.

Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological

Bisphosphonates in breast cancer.

Molecular mechanisms of action of bisphosphonates: current status.

P2888

1471-2407-9-154

P304

154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-9-154

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24438764

http://www.w3.org/2001/XMLSchema#string

P6179

1044834176

http://www.w3.org/2001/XMLSchema#string

P698

19454038

http://www.w3.org/2001/XMLSchema#string

P932

2694816

http://www.w3.org/2001/XMLSchema#string